Goal and research strategy of the Lustgarten Foundation
The intent of this program is to provide seed funding for highly innovative research with significant potential to accelerate the mission of the Lustgarten Foundation. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom. Proposals that involve collaborations across groups or that bring new expertise and/or technology into the field will be preferred.
Preliminary data is not required in the proposal, but the underlying premise or hypothesis must be plausible and testable, and the proposal must be focused on a well-defined goal that is achievable within the timeframe of the award.
Research topics are not restricted but may address topics relevant to the priorities and goals of the Lustgarten Foundation (Early Detection and Interception, Therapeutic Development, Personalized Medicine). Preference will be given to proposals addressing understudied and/or poorly understood aspects of pancreatic cancer biology.
The Innovation and Collaboration Program is not intended to support proposals aiming to incrementally advance existing hypotheses, ongoing areas of research, or proposals with the sole goal of generating novel reagents or resources.
Research Plan
The research plan must be submitted using the template available on ProposalCentral and may not exceed 3 pages, including figures and tables, but not including references. The research plan should include the following information: Statement of Innovation and Significance to Pancreatic Cancer, Specific Aims, Research Design and Methods, Potential Impact and Next Steps if Successful.
Incentive and Award funding program
A. Requested budgets will be considered and evaluated as part of the competitive selection process.
B. Grants up to $110,000 (including indirect costs) for one year will be considered.
C. Indirect costs may not exceed a maximum of 10% of direct costs.
D. PIs may use the NIH Salary Cap if the base salary exceeds the federal capitation.
E. Bi-annual scientific progress report and financial reports will be required.
F. Funded investigators will be expected to have regular interaction with Lustgarten Foundation scientific staff and will be expected to be willing to interact and/or collaborate with the larger network of Lustgarten Foundation-funded investigators and laboratories.
The strongest predictor of funding success is a proposal that is laser-focused on pancreatic cancer:
Pancreatic ductal adenocarcinoma (PDAC)
Early detection & screening biomarkers
Tumor microenvironment & stroma dynamics
Immunotherapy mechanisms & overcoming resistance
Metabolic reprogramming
KRAS signaling & downstream vulnerabilities
Single-cell / spatial / multi-omics of PDAC
Therapeutic resistance & metastasis biology
DNA damage response & synthetic lethality in PDAC
❗ Generic oncology proposals almost never get funded unless the link to pancreatic cancer is extremely strong.
The foundation has several targeted programs:
🔹 Research Grants
Hypothesis-driven, mechanistic or translational PDAC biology
Typically requires strong preliminary data
🔹 New Investigator Awards
For early-career independent PIs
Must demonstrate independence + trajectory
Mentorship letters and environment matter greatly
🔹 Innovation & Technology Grants
High-risk, high-reward ideas
Cutting-edge technologies (single-cell, spatial, machine learning, model systems)
🔹 Clinical Accelerator Initiative
Highly translational
Clinical trials, therapeutic development
Requires access to patients and infrastructure
🔹 Collaborative Team Science Grants
Multi-PI, multidisciplinary
Strong justification for collaboration required
Predictor: A perfect match between your project scope + career stage + platform and the targeted mechanism.
Lustgarten-funded studies almost always include:
Proof-of-concept experiments
Feasibility demonstrated in PDAC cell lines, organoids, or PDX models
Early mechanistic insights
Pilot biomarker results
Evidence the approach will work in PDAC, not just in other tumor types
Predictor: The presence of substantial preliminary data is a major competitive advantage.
Lustgarten reviewers favor realistic, high-quality models:
Patient-derived organoids (PDO)
Patient-derived xenografts (PDX)
Genetically engineered mouse models (KPC/KRAS-driven models)
Single-cell and spatial transcriptomics
High-quality PDAC patient cohorts
Predictor: Using state-of-the-art human PDAC models drastically improves competitiveness.
Lustgarten values bold ideas that can change the field:
New therapeutic strategies for KRAS-mutant tumors
First-in-field biomarker platforms
Approaches to overcome dense stroma and immunosuppression
Highly novel drug discovery targets
Disruptive technologies for early detection
Predictor: Proposals must be innovative and transformative, not incremental.
Lustgarten strongly emphasizes clinical relevance, such as:
Clear path to clinical trial
Biomarker ready for translation
Therapeutic candidates with near-term potential
Studies addressing treatment-resistant PDAC
Predictor: Translational potential is a dominant scoring category.
Reviewers expect:
Publications in pancreatic cancer or closely relevant topics
Demonstrated expertise in PDAC biology or tumor immunology
Evidence of independence (distinct niche from mentor)
Successful delivery of past research projects
Predictor: Strong track record is essential, especially for mid-career grants.
Team science is often favored, especially when:
Pairing computational + experimental expertise
Integrating clinicians for translational pipelines
Using shared resources (biobanks, imaging, sequencing)
Crossing multiple institutions to access unique samples or platforms
Predictor: Collaboration strengthens feasibility and impact — but only if it’s mission-critical.
Well-designed proposals include:
2–3 tightly structured aims
Realistic 1–2 year milestones
Go/no-go decision points
Backup approaches
Quantifiable outcomes
Predictor: A tightly scoped, feasible plan is crucial.
Winning proposals are:
Clear, compelling, and logically structured
Heavy on significance and rationale
Strong in methodological rigor
Easy for both biologists and translational reviewers to understand
Predictor: Strong writing often distinguishes funded from unfunded applications of similar scientific quality.
| Predictor | Why It Matters |
|---|---|
| PDAC-specific focus | Core eligibility; biggest scoring factor |
| Mechanism alignment | Ensures fit with reviewer expectations |
| Strong preliminary data | Demonstrates feasibility |
| Relevant PDAC models | Increases translational relevance |
| Innovation + high impact | Central Lustgarten priority |
| Clinical/Translational relevance | Key mission driver |
| Investigator track record | Reviewer confidence driver |
| Strategic collaboration | Amplifies feasibility & scope |
| Focused aims | Fits 1–2 year grant framework |
| Clear, polished writing | Increases reviewer enthusiasm |
A. Engaged in significant pancreatic cancer and/or relevant focus area research as a Principal Investigator.
B. Holds an independent faculty position or equivalent.
C. Willingness to interact and/or collaborate with the larger network of Lustgarten Foundation-funded investigators and laboratories.
Sponsor Institute/Organizations: Lustgarten Foundation
Sponsor Type: Corporate/Non-Profit
Address: 504 RXR Plaza Uniondale, NY 11556
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Jan 05, 2026
Jan 05, 2026
$110,000
Affiliation: Lustgarten Foundation
Address: 504 RXR Plaza Uniondale, NY 11556
Website URL: https://lustgarten.org/innovation-collaboration-rfa/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.